AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.6 |
Market Cap | 260.17M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.42 |
PE Ratio (ttm) | -6.21 |
Forward PE | n/a |
Analyst | Buy |
Ask | 2.98 |
Volume | 169,706 |
Avg. Volume (20D) | 129,378 |
Open | 2.64 |
Previous Close | 2.61 |
Day's Range | 2.60 - 2.83 |
52-Week Range | 2.25 - 4.98 |
Beta | undefined |
About ACIU
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The comp...
Analyst Forecast
According to 2 analyst ratings, the average rating for ACIU stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 359.77% from the latest price.
Next Earnings Release
Analysts project revenue of $556.43K, reflecting a -96.67% YoY shrinking and earnings per share of -0.19, making a 216.67% increase YoY.